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Abstract
Introduction:	Morbidity	and	mortality	attributed	 to	 lung	cancer	 remain	at	high	 levels,	 especially	where	men	are	concerned.	
The	surgery	for	lung	cancer	involves	removing	neoplastic	lesions	in	order	to	save	the	largest	possible	part	of	the	healthy	lung.	
Of	importance	is	also	pre-	and	post-surgical	rehabilitation.	The	aim	of	this	thesis	is	to	gauge	the	quality	of	life	of	the	patients	who	
have	had	their	lung	cancer	surgically	removed.	
Material and methods:	The	study	was	conducted	on	72	patients	(52	men	and	20	women)	after	surgical	removal	of	lung	cancer.	
The	subjects	were	examined	prior	to,	a week	after	and	six	months	following	surgery.	The	investigation	employed	the	standardised	
questionnaires	to	assess	the	quality	of	life,	i.e.	EORTC	QLQ-C30	and	EORTC	QLQ-LC13,	as	well	as	the	visual	analogue	pain	scale	
(VAS).	Statistical	analyses	were	performed	using	the	Anova	Friedman	test	and	Dunna	test,	and	p-value	calculated	in	multiple	
comparisons	with	significance	level	assumed	at	p	<	0.05.
Results:	During	six	months	after	the	operation,	the	quality	of	life	deteriorated	in	relation	to	the	one	before	operation	as	evidenced	
by	the	functioning	scale	at	the	level	of	p	<	0.001.	Overall	symptom	scale,	as	well	as	symptomatic	scale	and	the	VAS	scale	sho-
wed	that	some	symptoms	increased	significantly	in	the	early	period	after	surgery	p	<	0.001,	then	with	the	passage	of	time,	the	
patients	felt	improvement,	however,	some	of	them,	e.g.	pain	sensations	can	persist	till	six	months	after	surgery.
Conclusions:	Surgical	removal	of	lung	cancer	is	associated	with	a significant	deterioration	of	the	quality	of	life	in	the	early	period	
after	surgery	and	can	persist	till	six	months	later.
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Introduction
Neoplastic diseases occupy a  leading 
position in the list of civilisation diseases 
and causes of death [1]. According to the World 
Health Organization (WHO), particular attention 
should be paid to carcinoma of the lungs, which 
is the most common cause of death among all 
malignant neoplasms. In 2018, carcinoma of the 
lungs caused the death of 388 000 patients in 
Europe [2, 3].
Neoplastic disease, especially in its advan-
ced stages, is associated with suffering, fati-
gue, shortness of breath, loss of appetite, we-
ight loss, the physical pain related to radical 
treatment, as well as mental pain, which can 
seriously affect quality of life in different di-
mensions [4, 5]. Several studies have indica-
ted a  relationship between overall survival 
and the differences pertaining to the quality of 
life of healthy persons compared to cancer pa-
tients. Recent studies have shown a significant 
correlation between the severity of symptoms 
of advanced neoplastic disease of the lungs and 
the length of the patient’s life [6]. Furthermore, 
modern palliative care and support from the 
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closest people can not only lead to significant 
improvement in the quality of life of patients, but 
also prolong the survival of those with non-small 
cancer [7]. However, to determine the worst symp-
toms impacting on the quality of life, one needs 
to examine which of the manifestations are the 
most burdensome for the patient. In the United 
States and Europe, there are some reports con-
cerning the severity of symptoms of persons with 
advanced carcinoma of the lungs, however, there 
remains a lack of similar studies on subjects with 
carcinoma of the lungs that has not yet progressed 
to the advanced stage [8–10].
Methods for treating microcellular non-small 
cell- and lung cancer vary considerably. Surgical 
treatment in stages I, II and IIIA is only used in the 
treatment of non-small cell lung carcinoma and is 
possible only in 20 to 30% of patients, because most 
subjects do not qualify for this treatment due to hi-
gher advancement of the disease. The purpose of this 
type of treatment is radical resection of the primary 
tumour and any metastases in the mediastinum 
and hilus of the lymph nodes. This is due to 
post-operative pain, lung ventilation disorders 
and other complications that may occur when 
performing a thoracotomy [11]. Unfortunately, the 
survival rate following surgical treatment is not 
satisfactory; it is often the cause of relapse leading 
to remote metastasis, which contributes to the fact 
that approximately 50% of patients operated on 
survive only five years following surgery. Many 
studies have shown that among some individu-
als who have already been diagnosed with the 
disease, micrometastases occur during treatment. 
For this reason, following surgery, chemotherapy 
and radiation therapy are the most commonly 
used treatment methods — they are also applied 
in the treatment of smallcell carcinoma [12, 13].
The assessment of the quality of life 
is useful not only in a  subjective evaluation 
of the health status of the patient, but also in 
the monitoring of drugs and their effects on 
the health of the patient. This is done using 
a number of questionnaires aimed at investigating 
a disease entity. One such research tool for people 
suffering from lung cancer is the European Or-
ganisation for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30) 
with the lung cancer module QLQ-LC13 [14]. 
Nowadays the high quality of life of pa-
tients after cancer surgical treatment is one 
of the main goals of comprehensive treatment [15]. 
However, surgical treatment of lung cancer is so 
invasive that it lowers QoL in the early period 
after surgery, nevertheless, with the passage of 
time, in the period of convalescence after the 
procedure, the patient should feel improvement 
in functioning in various spheres of life. The aim 
of the current study was to assess the quality of 
life of the patients before, the week after and six 
months following the surgical removal of lung 
cancer. 
Material and methods
Description of the study group
The initial number of patients who entered 
the study amounted to 112 persons treated in the 
Department of Chest Surgery at the Specialist 
Team of Tuberculosis and Lung Diseases. The 
incompleteness of the results did not allow every-
one to be included in the analysis. After applying 
the exclusion criterion, a  total of 72 patients 
(20 women and 52 men) after surgical treatment 
of lung cancer were examined. The age of the 
subjects ranged from 40 to 78 years (average 62.4 
years; standard deviation = 8.9). 
Procedure
Data were collected from February 2014 to 
November 2017. The study included patients qu-
alified for surgery for the removal of the lung lobe 
or the entire lung, who gave their consent to the 
test, and the exclusion criteria were as follows: no 
consent for the study, incomplete results, e.g. no 
interview during follow up visit within 6 months 
after the surgery. The individuals qualified for 
the study were at the stage of surgical treatment. 
The attending physician decided about further 
treatment. Some of the subjects had adjuvant 
chemotherapy and radiotherapy. After the surge-
ry, each person was qualified for rehabilitation.
Research tools
Research in the form of medical history was 
performed for each patient prior to surgery, a week 
after the procedure and was repeated six months 
after the operation. Each person that agreed to 
participate in the study was informed about the 
purpose of testing and the fact that he/she could not 
answer some of the questions or withdraw his/her 
consent to their conduct. All of the patients before 
and a week after surgery participated in rehabili-
tation.
The research method was a standardised qu-
estionnaire for assessing the quality of life of pe-
ople with cancer using the EORTC QLQ-C30 (3.0 
version), as well as the additional module EORTC 
QLQ-LC13, designed for patients with carcinoma 
of the lungs; a VAS pain scale was also used. 
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The EORTC QLQ- C30 and LC13 qu -
estionnaires are standardised research tools 
to assess the quality of life in oncological pa-
tients, as well as the impact of cancer treatment 
on the patient’s functioning. The EORTC QLQ
-C30 questionnaire consists of 30 questions which 
are grouped in five scales assessing the patient’s 
functioning in the physical, emotional and social 
sphere, as well as social roles, memory and con-
centration. The next three subscales are used to 
evaluate symptoms such as nausea and vomiting, 
fatigue and pain sensations. The final subscale 
concerns the overall assessment of health and the 
quality of life. The answers are scored from 0 to 7 
points, where the higher score represents higher 
quality of life. The QLQ-LC13 module assesses the 
severity of symptoms in the scale from 0 to 100 
points, where the highest result means the best 
state of being of the patient [16]. The consent for 
the use of the above-mentioned questionnaires in 
the study was obtained from the European Orga-
nisation for Research and Treatment of Cancer 
(Brussels, 2014).
Tools/statistical tests
Statistical analyses were performed using the 
Anova Friedman test and Dunna test (post-hoc), 
and calculated the p-value in multiple compari-
sons with significance level at p < 0.05. Statistical 
analysis was carried out with the Statistica 13.1 
software (StatSoft, Poland). 
Statistical examination of the collected 
data was based on a comparison between each 
of the three or four groups, on the basis of the 
observation of the same group of objects measured 
three times in the case of the EORTC-QLQ-C30 
and LC 13 (before, a week and a half and six 
months after surgery), and four times in the case 
of the VAS (before, the day after, one week and 
six months after surgery). 
Due to a wide range of the studied functio-
nal areas included in the questionnaires EORTC 
QLQ-C30 and EORTC QLQ-LC13, the focus was 
on selected areas, i.e. Functional scale, Overall 
Symptom scale, Symptomatic scale, and pain sen-
sations that were analysed using the VAS scale and 
omitting e.g. self-assessment of the quality of life. 
Results
The distribution of points in the EORTC 
QLQ-C30 questionnaire before, a week 
and a half and six months after surgery: 
functioning scale 
The value of the coefficient p in the Freid-
man test was given as p < 0.001. To determine in 
detail the moments that mark differences within 
studies, multiple comparisons were analysed to 
achieve the final results. 
The outcomes of three consecutive me-
asurements of the functional scales were not 
equal (Friedman p < 0.001). They differed in 
the measurement before and after a week, and 
before and after six months. There were no 
significant differences in the measurements 
made after one week and six months in relation 
to each other. 
Changes in overall functioning were signifi-
cant between the studies where it concerned the 
time before surgery and one week following treat-
ment. Significant improvement or worsening was 
not observed six months after treatment (Table 1).
The distribution of points in the EORTC 
QLQ-C30 questionnaire before, a week 
and a half and six months after surgery: 
overall symptom scale
 The results of three successive scores of the 
scales of symptoms were not equal (Friedman 
p < 0.001). They differed in the measurement 
before and after a week, and before and after six 
months. There were no significant differences in 
the measurements made after one week and six 
months in relation to each other.
The intensity of feelings of discomfort, i.e., 
fatigue, nausea and vomiting, pain, shortness 
Table 1. EORTC QLQ-C30 Questionnaire - functional scales - analysis of results of repeated measurements 
Functional scales 
Measurement period
Mean
rank
Sum of
ranks
X SD Friedman’s 
Anova
Dunn’sTest (post-hoc)
p < 0.05
Before After a week After six months
Before 1.38 49.50 24.56 7.88 p	<	0.001 – 37 30.5
After	a	week 2.40 86.50 33.72 9.18 37 – 6.5
After	six	months 2.22 80.00 32.99 7.75 30.5 6.5 –
X	—	arithmetic	mean;	SD:	standard	deviation;	p-level	of	probability
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Table 2. EORTC QLQ-C30 Questionnaire - symptoms scales - analysis of results of repeated measurements
Symptoms scales
Measurement period
Mean
rank
Sum of
ranks
X SD Friedman’s 
Anova
Dunn’sTest (post-hoc)
Before After a week After six months
Before 1.03 37.00 4.06 7.76 p	<	0.001 – 60 45
After	a	week 2.69 97.00 32.55 10.52 60 – 15
After	six	months 2.28 82.00 23.29 9.98 45 15 –
X	—	arithmetic	mean;	SD:	standard	deviation;	p-level	of	probability
of breath, sleep disturbances, loss of appetite, 
constipation, diarrhoea increased significantly 
week after treatment compared to the state before 
the operation (p < 0,001). However, six months 
after treatment, symptoms significantly decreased 
(Table 2).
The distribution of points in the 
questionnaire EORTC – QLQ- LC 13 
before, a week and a half and six months 
after surgery: Symptomatic scale 
The results of three consecutive measu-
rements of the symptom scale were not equal 
(Friedman p < 0.001). They differed in the me-
asurement before and after a week, and before 
and after six months. There were no significant 
differences in the measurements made after one 
week and six months in relation to each other. 
The presence of symptoms such as dyspnoea, 
cough, haemoptysis, canker sore, trouble swal-
lowing, numbness of the limbs, hair loss, chest 
pain, pain in the arm and shoulder, and pain in 
other parts of the body was less frequent before 
medication, significantly intensified in the week 
after the operation and remained at the same high 
level six months following treatment (Table 3).
The distribution of points in the VAS scale 
before, the day after, one week and six 
months after surgery
The results of three consecutive measure-
ments of the VAS scale were not equal (Friedman 
p < 0.001). They differed in the measurement be-
fore and after the first day, before and after a week, 
after the first day and after six months and after 
a week and after six months. They did not differ 
in the measurement before and after six months 
and after the first day and after a week (Table 4).
The analysis showed an increase in pain the 
day after surgery, compared to pain experienced 
prior to the operation. Then, with the passing 
of time, the pain decreased significantly, but in 
the last measurement was no less than prior to 
treatment.
Discussion
Neoplastic disease is a  very stressful ill-
ness due to different prognoses for survival 
and various clinical treatment courses. The ra-
pid development of medical achievements has 
meant that the chances of survival among cancer 
patients have increased [17]. For most people, the 
disease still has negative associations with death, 
and many often tend to think of it as a chronic 
disease. Therefore, it is important to influence 
the improvement of the quality of life for those 
undergoing oncological treatment by attaching to 
it greater importance [18, 19].
Our study showed that the quality of life 
of patients, even six months after the operation, 
did not return to the state it had been before 
the operation. The quality of life before and one 
week after surgery had significantly deteriorated, 
Table 3. EORTC QLQ-CL13 Questionnaire — symptoms scales — analysis of results of repeated measurements
Symptoms scales
Measurement period
Mean
rank
Sum of
ranks
X SD Friedman’s 
Anova
Dunn’sTest (post-hoc)
Before After a week After six months
Before 1.15 41.50 6.87 8.25 P	<	0.001 – 47.5 44
After	a	week 2.47 89.00 22.07 7.03 47.5 – 3.5
After	six	months 2.38 85.50 21.14 9.86 44 3.5 –
X	—	arithmetic	mean;	SD:	standard	deviation;	p-level	of	probability
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then slightly got better six months after surgery. 
On the whole, some symptoms showed some im-
provement, e.g., nausea, vomiting, headache, short-
ness of breath and sleep disorders decreased. While 
the scale of functioning and scale of symptoms 
slightly ameliorated, the patients still experienced 
problems with physical functioning, shortness of 
breath and pain in the arm and chest [20, 21].
According to Wołowicka [22], surgery has 
a major impact on physical functioning in terms 
of performance and overall quality of life. With 
the passage of time following surgery, the quali-
ty of life improved. In our study, we also noted 
change for the better over time following surgery; 
however, improvement for the functioning scale 
and the scale of symptoms was small, while the 
largest advancement was noted for the scale of 
symptoms.
In relation to the mental dimension of the 
quality of life, this improved with the passage 
of time since surgery and the strongest symp-
toms of depression and clasp annoy patients 
in the perioperative period. These conclusions 
were also reached by other researchers [23, 24].
The majority of patients experienced weak-
ness and needed to rest. According to Wołowicka, 
approximately 30% of subjects in the later period 
following major surgery reported the impairment 
of physical activity [25]. Existing studies show 
that six months following surgery, long walks 
tired approximately 58% of respondents.
Our research demonstrated that the pain 
experienced was the highest the day after surgery. 
With time, it decreased significantly but ultima-
tely, did not reach the same level as before sur-
gery. In addition, studies have shown that chest 
pain occurred in more than two thirds of respon-
dents and that additionally, half of respondents 
felt pain in the arm or shoulder. Similar results 
were reported by Nowicki, who also observed 
the frequent occurrence of difficulty sleeping, 
dyspnoea, shortness of breath and a very high 
incidence of coughing, which corresponds to 
their own studies showing that only 19% of pa-
tients did not report cough after surgery, 89% felt 
dyspnoea, and 92% reported shortness of breath 
when walking of patients [21].
According to the study carried out by Ksią-
żek, the quality of life in terms of parameters such 
as nausea, lack of appetite, shortness of breath 
and pain was systematically improving with time, 
which is confirmed by their and other researchers’ 
testing [23]. Similar results were found in the 
studies conducted by Eton. Nausea and other ef-
fects of treatment were eliminated, because they 
were considered as related to treatment and not 
a symptom [24, 25].
Our own research, along with that of others, 
show that with time, the symptoms resulting from 
resection of the lung have a decreasing tendency. 
Unfortunately, in most patients, their physical 
condition worsens and is maintained even in the 
late period following the operation [26–28].
The research carried out in this paper made 
it possible to obtain results of the assessment 
of the overall quality of life among patients un-
dergoing surgery for lung cancer. The analysis 
allows concluding that tumour resection is bene-
ficial for the health of individuals. It is not only 
a  lifesaving treatment, but the best method 
for healing cancer. Although it involves pain 
and complications at an early stage, it is a com-
prehensive procedure that not only extends the 
life of the patient, but also has very good effects 
in terms of treatment.
Conclusions
Surgical removal of lung cancer is associated 
with a significant deterioration of the quality of 
life in the early period after surgery and can per-
sist till six months later.
Table 4. VAS scale — analysis of results of repeated measurements
VAS scale
Measurement 
period
Mean
rank
Sum of
ranks
X SD Friedman’s 
Anova
Dunn’s Test (post-hoc)
Before After the first 
day
After a week  After six 
months
Before 1.21 43.50 0.44 1.32 p	<	0.001 – 90.5 70 25.5
After	the	first	
day
3.72 134.00 7.58 2.51 90.5 – 20.5 65
After	a	week 3.15 113.50 5.36 1.90 70 20.5 – 44.5
After	six	months 1.92 69.00 1.89 1.04 25.5 65 44.5 –
X	—	arithmetic	mean;	SD:	standard	deviation;	p-level	of	probability
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